Fernandez-Martin Amelia, Gonzalez-Rey Elena, Chorny Alejo, Martin Javier, Pozo David, Ganea Doina, Delgado Mario
Instituto de Parasitologia y Biomedicina, CSIC, Avd. Conocimiento, PT Ciencias de la Salud, Granada 18100, Spain.
Ann N Y Acad Sci. 2006 Jul;1070:276-81. doi: 10.1196/annals.1317.026.
Multiple sclerosis (MS) is a disabling inflammatory, autoimmune demyelinating disease of the central nervous system (CNS). Despite intensive investigation, the mechanisms of disease pathogenesis remain unclear, and curative therapies are unavailable for MS. The current study describes a new possible strategy for the treatment of MS, based on the administration of the vasoactive intestinal peptide (VIP). Treatment with VIP significantly reduced incidence and severity of experimental autoimmune encephalomyelitis (EAE), an MS-related rodent model. VIP suppressed EAE neuropathology by reducing CNS inflammation and by selective blocking encephalitogenic T-cell reactivity, emerging as an attractive candidate for the treatment of human MS.
多发性硬化症（MS）是一种中枢神经系统（CNS）致残性炎症性自身免疫性脱髓鞘疾病。尽管进行了深入研究，但疾病发病机制仍不清楚，且尚无治愈MS的疗法。当前研究描述了一种基于给予血管活性肠肽（VIP）治疗MS的新的可能策略。用VIP治疗可显著降低实验性自身免疫性脑脊髓炎（EAE，一种与MS相关的啮齿动物模型）的发病率和严重程度。VIP通过减轻中枢神经系统炎症和选择性阻断致脑炎性T细胞反应性来抑制EAE神经病理学，成为治疗人类MS的有吸引力的候选药物。
